Natural Versus Programmed Frozen Embryo Transfer (NatPro)

Running, not enrolling · Phase 3

Conditions studied: Pregnancy Related, Pre-Eclampsia

In brief

NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing frozen embryo transfer (FET) will be randomized to receive either a modified natural cycle (corpus luteum present) or a programmed cycle (corpus luteum absent).

Key facts

Study ID

NCT04551807

Run by

JHSPH Center for Clinical Trials

People needed

788

Starts

2020-09-16

Expected to finish

2026-04-01

Last updated by the study team

2025-05-16

Who can join

Age: 18 and older, up to 41. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• To be eligible, subjects must meet all these criteria:
• Age 18-39 years at the time that embryos were created if no PGT testing was performed. If PGT testing was performed and indicates that an embryo is euploid, the patient can be included if she was age 18-41 years at the time that the embryo was created.
• Age 18-41 years at the time of randomization as advancing age itself becomes a significant risk for preeclampsia
• Normal uterine cavity as assessed by saline infusion sonohysterogram, hysterosalpingogram, or hysteroscopy within one year of the enrollment visit, and repeated at the discretion of the investigator
• Regular menstrual cycle length (approximately 24-35 days) indicative of ovulatory cycles.
• Willing to undergo elective single embryo transfer
• Body Mass Index <=40
• If Body Mass Index is over 30 or individual has other risk factors for diabetes, normal hemoglobin A1C
• Prior to enrollment, participant will have at least one vitrified blastocyst with euploid result by pre-implantation genetic testing (PGT-A) or at least one vitrified blastocyst of fair or better morphologic quality if no PGT-A results are available.
• Willingness to be randomized to either a modified natural or programmed cycle, with a willingness to administer intramuscular progesterone in oil if assigned to the programmed cycle.
• Normal thyroid stimulating hormone (TSH), according to local laboratory standards (or TSH level with a clinically insignificant abnormality per the site director), within one year of study enrollment and repeated at the discretion of the investigator. Use of thyroid medication is permitted.

You may not qualify if…

• To be eligible, subjects must not meet any one of these criteria:
• Medical contraindication to pregnancy
• Embryos created using donor oocytes
• Embryo donation
• Gestational carrier
• Reciprocal IVF (one female partner carrying pregnancy, other female partner as source of eggs)
• Fresh embryos created from frozen oocytes. Patients with frozen embryos created from frozen oocytes can be included.
• Recurrent implantation failure defined as no clinical pregnancy with ≥ 2 prior consecutive embryo transfers unless patient also had successful live birth between or after the failed embryo transfers
• Anti-phospholipid antibody syndrome or rheumatologic disease requiring chronic systemic medications
• Uncontrolled diabetes mellitus
• History of >1 pregnancy loss in the second or third trimester
• Uncontrolled hypertension
• Untreated hydrosalpinx (i.e., hydrosalpinx in situ which has not been ligated or removed)
• Mullerian uterine anomaly, if not correctable
• Physician recommendation to perform the embryo transfer outside of the timing specified by the protocol
• Contraindication to any medication which must be used in preparation for the frozen embryo transfer (i.e., estradiol, progesterone, hCG)

Where it is running

• University of California San Francisco — San Francisco, California, United States
• Stanford University — Sunnyvale, California, United States
• Yale — Orange, Connecticut, United States
• Fertility Institute of Hawaii — Honolulu, Hawaii, United States
• Northwestern University — Chicago, Illinois, United States
• Johns Hopkins — Baltimore, Maryland, United States
• Shady Grove Fertility — Rockville, Maryland, United States
• Boston IVF — Waltham, Massachusetts, United States
• University of Rochester — Rochester, New York, United States
• Atrium Health — Charlotte, North Carolina, United States
• Cleveland Clinic Foundation — Beachwood, Ohio, United States
• University of Oklahoma — Oklahoma City, Oklahoma, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• CARE Fertility — Bedford, Texas, United States
• West Virginia University Center for Reproductive Medicine — Morgantown, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.